Since nucleic acid sensors, such as the retinoic acid inducible gene (RIG)-1 and the melanoma differentiation-associated gene 5 (MDA5), activate type I IFN via TBK-1 signaling, the use of TBK inhibitors might represent an alternative strategy in SLE patients, with fewer side effects than the conventional immunosuppressive drugs [152]. This evidence concerns the gene IFIH1 and systemic lupus erythematosus.